Pacific Biosciences of California, Inc. (NASDAQ:PACB)

CAPS Rating: 2 out of 5

Results 1 - 20 of 27 : 1 2 Next »

Recs

0
Member Avatar Paco57 (21.01) Submitted: 1/12/2016 9:30:05 PM : Outperform Start Price: $12.11 PACB Score: -23.15

Weird Science.

Recs

0
Member Avatar NHWeston102 (< 20) Submitted: 10/7/2015 11:59:46 AM : Outperform Start Price: $7.59 PACB Score: +20.90

If they can beat Illumina at their own gene=sequencing game, they're gonna get bot.

Recs

1
Member Avatar TSIF (99.96) Submitted: 10/5/2015 3:38:06 PM : Underperform Start Price: $5.29 PACB Score: -66.26

Releasing a lower cost option should ultimately be good for the bottom line...at least in this case.
Sometimes too many models confuses customers and erodes the higher margin upper end of the offering, but in this case, the high end was so high, virtually no one could afford it.

I misjudged the entry here, though I did account for the huge short interest that had to cover, and potentially re-up and cover again...day traders should have exited, and speculators seem marginal, most holders anxious to get out on the bump with part of their shirt back.

Even if the lower end takes off, the cash flow here is horrendous an it will take time to turn the tide. Losing 60M yoY and S&G and cost of revenue will remain high, if not higher due to the mix. P/B 13X. Way over valued.

Hope to ride down some...$5 or so...not one to get greedy as I like this little stub, maybe in a year or two...might miss a buyout before then, but shouldn't bet on those....

Recs

0
Member Avatar tmjlowe (< 20) Submitted: 1/24/2015 11:17:27 PM : Outperform Start Price: $7.92 PACB Score: +19.09

Their new chemistries developed for their genome long-read sequencing machines are being recognized as being the best way now to completely sequences new genomes (better than Illumina, which has trounced them up until now). This stock could really improve this year as more people recognize this is the best way to sequence new genomes.

Recs

0
Member Avatar jdubbau (92.93) Submitted: 9/4/2014 7:15:17 AM : Outperform Start Price: $5.16 PACB Score: +75.39

Long term trend of genomic sequencing in health care applications will create a new competitive landscape. Pacific Bio has a differentiated approach that will attract a segment of the (growing) market.

Recs

0
Member Avatar champagnepowder (69.11) Submitted: 2/26/2014 4:26:21 PM : Outperform Start Price: $7.19 PACB Score: +20.37

Technology is rule breaking and management is focused on improving throughput. Sales have been going up and industry seems to be providing some free promotion with all the papers that are being written/published.

Recs

0
Member Avatar elks20 (< 20) Submitted: 5/26/2013 7:26:38 AM : Outperform Start Price: $2.68 PACB Score: +211.00

New product, product updates, growth ahead

Recs

0
Member Avatar panesh (58.10) Submitted: 1/24/2013 11:47:01 AM : Outperform Start Price: $2.49 PACB Score: +223.00

This stock has been much higher than this and will return to 2 bagger status

Recs

0
Member Avatar gtechie (61.42) Submitted: 1/15/2013 2:58:49 PM : Outperform Start Price: $2.79 PACB Score: +183.40

Has it finally turned the corner? It's been up pretty big lately, and I'm making a CAPS bet that it'll continue.

Recs

0
Member Avatar mattyabe (32.74) Submitted: 6/23/2012 9:17:32 PM : Outperform Start Price: $2.00 PACB Score: +290.96

Both PACB and GNOM are beat up right now, and it's only a matter of time before one of them takes off. It may be smart to buy both instead of guessing which one

Recs

1
Member Avatar DebbyDo101 (37.70) Submitted: 3/25/2012 2:55:24 AM : Outperform Start Price: $3.99 PACB Score: +85.22

This is the risky one, but they will either pull the rabbit out of the hat or not. They have a machine that does gene resequencing for about a thousand dollars.
A stock at the price I would be willing to invest in because I believe in the product and will put some money behind it. Just not a lot of money. All I can lose is 3.93 a share.

Recs

0
Member Avatar CATomla (< 20) Submitted: 2/7/2012 12:57:52 PM : Outperform Start Price: $4.87 PACB Score: +40.66

No place to go but up.

Recs

0
Member Avatar badgervb (< 20) Submitted: 10/3/2011 11:45:08 PM : Underperform Start Price: $2.97 PACB Score: -120.38

investigation...and i own some. i am the kiss of death!

Recs

0
Member Avatar Keekers44 (53.82) Submitted: 9/3/2011 12:39:41 PM : Outperform Start Price: $5.79 PACB Score: -11.57

This highly volitile stock is definately a speculative play for a while. Shares droped 30% after some bad news regarding gross margins. I believe that drop was a bit drastic.

Recs

0
Member Avatar Blackarrow1969 (44.80) Submitted: 8/5/2011 6:51:37 PM : Outperform Start Price: $6.45 PACB Score: -23.30

They had a great quarterly report but got creamed due to a JPM downgrade. It's a long-term spec stock with great potential.

Recs

0
Member Avatar johnnymack91362 (< 20) Submitted: 6/30/2011 1:47:50 PM : Outperform Start Price: $11.63 PACB Score: -64.95

gamble time

Recs

0
Member Avatar mtnv110960 (52.97) Submitted: 6/24/2011 7:39:58 PM : Outperform Start Price: $11.46 PACB Score: -65.97

Mark this date down. Who buys 1.5 million shares after hours? Something is going on.............

Recs

0
Member Avatar latinoeconomist (28.69) Submitted: 6/23/2011 4:34:32 AM : Outperform Start Price: $10.83 PACB Score: -64.55

Is gearing up for explosive growth.

Recs

0
Member Avatar polterziets (22.84) Submitted: 6/4/2011 5:03:54 PM : Outperform Start Price: $11.54 PACB Score: -66.19

i like where their technology is going

Recs

0
Member Avatar simsimmarvin38 (< 20) Submitted: 5/29/2011 3:42:29 AM : Outperform Start Price: $12.20 PACB Score: -65.33

Clearly the most powerful technology with a large void to fill in the sequencing space. Granted it will have a slow start as centers have to phase out current technology over time but once momentum picks up this run will be hard to stop.

Results 1 - 20 of 27 : 1 2 Next »

Featured Broker Partners